Skip to main content
Figure 2 | Arthritis Research & Therapy

Figure 2

From: Calprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis

Figure 2

Changes in serum biomarkers between baseline (week 0) and week 2 of infliximab (IFX) (n = 18) versus placebo (PLC) (n = 19) treatment in active spondyloarthritis (SpA). Paired t-tests were performed. Data are represented as mean (standard error of the mean), *P <0.05. hs-CRP, high-sensitivity C-reactive protein; IL-6, interleukin-6; PTX-3, pentraxin-3; alpha-2-MG, alpha-2-macroglobulin; MMP-3, matrix metalloproteinase-3; VEGF, vascular endothelial growth factor.

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us